The biggest differences between the development of a biosimilar and a generic medicine lie primarily in the preclinical and clinical stages.
Huub Schellekens
Advertisement
Huub Schellekens is Professor in the Department of Pharmaceutical Sciences and Innovation Studies at Utrecht University, The Netherlands.
Articles by Huub Schellekens
Advertisement
Latest Updated Articles
- What Is Hindering The Uptake Of Biosimilars?
Published: August 1st 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Clearing Hurdles in Sustainability, AI, and CDMO Partnerships
2
Dosage Form Innovations: A CPHI Frankfurt Conversation with Lonza’s Frank Romanski, Part One
3
PharmTech Weekly News Roundup — Week of October 27, 2025
4
Drug Digest: Strategic Alliances and Technology Integration in the Evolving Biopharma Landscape
5
